TERT mutations in thyroid cancers
Recent studies which discovered telomerase reverse transcriptase (TERT) gene promoter mutations in human melanomas represent a novel genetic mechanism in human tumorigenesis. Liu and colleagues identified, for the first time, common TERT promoter mutations in thyroid cancers, which are particularly prevalent in aggressive subtypes. The discovery of this novel genetic background in thyroid cancers opens exciting new opportunities for biological and clinical research. Read the full article in Endocrine-Related Cancer 20 603—610, DOI: 10.1530/ERC-13-0210.
Publication date: Available online 20 August 2019Source: European Journal of Surgical OncologyAuthor(s): Ashok R. Shaha, R. Michael Tuttle
Authors: Choi KW, Kim Y, Fava M, Mischoulon D, Na EJ, Kim SW, Shin MH, Chung MK, Jeon HJ Abstract BACKGROUND The number of thyroidectomies in South Korea has been increasing rapidly due to extensive check-ups for thyroid cancer. However, few studies have examined the association between thyroidectomy and major depressive disorder (MDD). We investigated the association between thyroidectomy and the risk of MDD. METHODS A population-based, electronic medical records database from South Korea was used to identify 187,176 individuals who underwent partial or total thyroidectomy between 2009 and 2016. A self-controlled ...
We report the development of hidradenitis suppurativa (HS) in a patient after initiation of treatment with sorafenib. To our knowledge, sorafenib-induced HS in the axillary and inguinal skin folds has not been previously reported. A 33-year-old male on sorafenib for papillary thyroid cancer presented for evaluation of “boils” that began when he initiated chemotherapy 5 years prior and had continued to progress.
ConclusionsSubclassification of AUS/FLUS into three groups based on cytopathologic findings alone not only improved the triage of patients for subsequent clinical management but also effectively stratified the risk of malignancy.
Conditions: BRAF NP_004324.2:p.V600M; BRAF V600E Mutation Present; Metastatic Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVB Differentiated T hyroid Gland Carcinoma AJCC v8 Interventions: Drug: Binimetinib; Drug: Encorafenib; Biological: Nivolumab Sponsors: OHSU Knight Cancer Institute; National Cancer Institute&nbs...
No abstract available
Conclusions: Because of the low metastasis rate in level V lymph nodes, the lack of benefit for recurrence, the longer hospital stay and the higher cost associated with LVD, N1b PTMC patients without clinical level V metastasis may not need to undergo routine dissection. Prophylactic LVD may be recommended only for patients with N1b PTMC with 3-level simultaneous metastasis.
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.